• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intravacc touts preclinical, non-human results for COVID-19 nasal spray vaccine

April 7, 2021 By Sean Whooley

IntravaccIntravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects.

Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day one and day 21, according to a news release.

One group of each animal received a vaccine based on OMVs mixed with rSp and the other a vaccine based on OMVs coupled to rSp based on Intravacc’s proprietary OMV click technology. Control animals received only OMVs or only rSp, respectively.

In the mice that received the CovOMV and CovOMV click vaccines, 30% and 90% virus-neutralizing antibodies were detected, respectively. Both candidate vaccines produced neutralizing antibodies in all hamsters, but the level in the click group was slightly higher compared to the other.

Intranasal vaccination with both OMV-rSp vaccine candidates resulted in complete protection after challenge, with zero lung lesions detected by histopathology, seven days after hamsters were challenged. All hamsters that received the vaccines showed reduced systemic weight loss after challenge, while unvaccinated animals or those in the control lost more than 10% of their bodyweight.

“We are very pleased with this pre-clinical data of our intranasal SARS-CoV-2 candidate vaccine,” Intravacc CEO Dr. Jan Groen said in the release. “This allows us to move quickly towards an in-human combined phase I and II clinical trial. Based on historical scientific and clinical data generated at Intravacc, I am convinced that we are well-positioned for the further development of this vaccine. This and previous data clearly demonstrate the value of our OMV-vaccine technology for future development of other preventive and therapeutic vaccines.”

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials Tagged With: coronavirus, COVID-19, COVID-19 vaccine, Intravacc

IN CASE YOU MISSED IT

  • Lyra Therapeutics appoints new chief medical officer
  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS